Archiv
Archiv anzeigen:
bis


Minimally Invasive Surgery for Esophageal Cancer

David H. Ilson, MD, PhD reviewing Mariette C et al. N Engl J Med 2019 Jan 10

The rate of major complications was significantly lower with hybrid minimally invasive esophagectomy than with conventional transthoracic open esophagectomy.


Luspatercept for Beta-Thalassemia

David Green, MD, PhD reviewing Piga A et al. Blood 2019 Jan 7

Luspatercept increased hemoglobin and reduced transfusion burden in a phase II study.


Managing Patients with Low von Willebrand Factor Levels

David Green, MD, PhD reviewing Lavin M and O'Donnell JS. Blood 2018 Dec 21

Diagnosing and treating patients with VWF levels in the range of 30 to 50 IU/dL.


Screening Patients for Pancreatic Cancer: Making Some Progress

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Paiella S et al. Am J Gastroenterol 2018 Dec 11

Image-based screening detected pancreatic malignancies in some high-risk individuals.


Microsatellite Instability in Prostate Cancer and the Role of Immune Checkpoint Blockade

Robert Dreicer, MD, MS, MACP, FASCO reviewing Abida W et al. JAMA Oncol 2018 Dec 27, Reichert ZR et al. JAMA Oncol 2018 Dec 27

MSI may be a biomarker for checkpoint inhibitor response.


Adjuvant FOLFIRINOX vs. Gemcitabine for Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Conroy T et al. N Engl J Med 2018 Dec 20, Kindler HL. N Engl J Med 2018 Dec 20

FOLFIRINOX significantly improved survival but increased toxicity.


Report from the 60th American Society of Hematology Annual Meeting

David Green, MD, PhD

Highlights of the latest research


The 2018 San Antonio Breast Cancer Symposium

William J. Gradishar, MD

Highlights of the latest research


Genetic Testing for Breast Cancer: How Effective Are Guidelines?

Henry Mark Kuerer, MD, PhD, FACS reviewing Beitsch PD et al. J Clin Oncol 2018 Dec 7, Milliron KJ and Griggs JJ. J Clin Oncol 2018 Dec 7

National Comprehensive Cancer Network guidelines for multigene panel testing miss nearly half of patients with actionable variants.


NEJM Journal Watch Oncology and Hematology Top Stories of 2018

William J. Gradishar, MD

A perspective on the most important research in the field from the past year


Archiv
Seite von 78
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen
Kantonsspital St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Im «New England Journal of Medicine» sind wieder einige interessante, auch «practice changing» Publikationen erschienen.

Kommentar weiterlesen

Enzalutamide for Castration-Resistant PSA-Only Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hussain M et al. N Engl J Med 2018 Jun 28, Smith MR. N Engl J Med 2018 Jun 28

Metastasis-free survival was significantly improved with enzalutamide versus placebo.


First-Line Atezolizumab for Metastatic Nonsquamous NSCLC

Anne S. Tsao, MD reviewing Socinski MA et al. N Engl J Med 2018 Jun 14

Adding atezolizumab to bevacizumab and chemotherapy improved survival in chemotherapy-naive patients with non–small-cell lung cancer, regardless of EGFR or ALK mutation status.


Cytoreductive Nephrectomy for Metastatic Kidney Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Méjean A et al. N Engl J Med 2018 Jun 3, Motzer RJ and Russo P. N Engl J Med 2018 Jun 3

Adding nephrectomy to standard sunitinib therapy did not improve survival in patients with poor- and intermediate-risk disease.


ASCO 2018 Report — Breast Cancer

William J. Gradishar, MD

Highlights of the latest treatments


Intensive Surveillance for Colorectal Cancer

David H. Ilson, MD, PhD reviewing Wille-Jørgensen P et al. JAMA 2018 May 22, Sanoff HK. JAMA 2018 May 22

More- versus less-frequent testing did not improve survival after curative treatment for patients with stage II–III disease.


Fewer Patients with Breast Cancer Require Chemotherapy

William J. Gradishar, MD reviewing Sparano JA et al. N Engl J Med 2018 Jun 3

Outcomes were noninferior with endocrine therapy alone versus chemo-endocrine therapy in patients with intermediate recurrence scores.


Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Henry Mark Kuerer, MD, PhD, FACS reviewing Wapnir IL et al. J Clin Oncol 2018 Apr 10

Long-term results confirm a benefit for ER-negative but not ER-positive patients.


Neoadjuvant Nivolumab for Resectable Lung Cancer

Anne S. Tsao, MD reviewing Forde PM et al. N Engl J Med 2018 Apr 16

A major pathological response was seen in 45% of patients.


First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Hellmann MD et al. N Engl J Med 2018 Apr 16

Progression-free survival was improved versus chemotherapy for patients with high tumor mutation burden.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.